Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab with Chemoradiation and Maintenance in Pancreatic Cancer
NCT00114179Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2005
- Primary completion
- May 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in Pancreatic ductal adenocarcinoma (PDAC), sponsored by National Cancer Institute. Primary endpoint: Overall Survival Rate at 1 year. Started Jan 2005; status: completed.
02
Drugs
bevacizumab
03
Conditions
Pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00114179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00114179.